Cognitive dysfunction in elderly patients with depression based on chronic brain ischemia: vortioxetine (Brintellix) experience
Abstract
The effect of Vortioxetine (Brintellix) on the condition of cognitive functions and depression symptoms has been studied on a small population of middle aged and elderly patients with depression developed on the background of chronical brain ischemia. Patients were taking Vortioxetine in the dose of 10 mg during 6 months. Vortioxetine eliminated both cognitive dysfunction and symptoms of depression in patients of both age groups. Cognitive remission as well as absence of relapses continued within 6 months after medication cancellation. Vortioxetine showed a good acceptability and safety in the study population.
About the Authors
Yu. V. Zhitkova
Interregional Clinical and Diagnostic Center
Russian Federation
Russian Federation
D. R. Hasanova
Interregional Clinical and Diagnostic Center; Kazan State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Аведисова А.С. Нейропластичность и патогенез депрессии: новые данные // Психиатрия и психофармакотерапия. - 2004. - Т.6. - № 6. - С.312-314.
2. Афтанас Л.И. Депрессия и нейродегенерация: новые стратегии диагностики и терапии // Наука и зпервых рук. - 2017. - №1. - С. 41-49.
3. Безпрозванный И.Б. Система кальциевой сигнализации при нейродегенерации // Actanaturae. - 2010. - T.2. - С.80-88.
4. Боголепов Н.Н. Закономерности реализации механизмов синаптогенеза в коре большого мозга взрослых крыс после кратковременной тотальной остановки системного кровотока / Боголепов Н.Н., Семченко В.В., Степанов С.С. // Структурно-функциональные и нейрохимические закономерности асимметрии и пластичности мозга. - М. - 2005. - C.51-54.
5. Гусев Е.И., Боголепова А.Н. Депрессивные расстройства у больных с цереброваскулярной патологией. Методические рекомендации Департамента здравоохранения г. Москвы. - 2008. - №35. - 28c.
6. Рудницкая Е.А., Колосова Н.Г, Стефанова Н.А. Анализ вклада изменения нейротро фического обеспечения в развитие признаков болезни Альцгеймера у крыс OXYS // Биохимия. - 2017. - T.82(3). - С.460-469.
7. Семченко В.В., Степанов С.С., Боголепов Н.Н. Синаптическая пластичность головного мозга (фундаментальные и прикладные аспекты). - Омск.: Омская областная типогра фия. - 2008. - 408с.
8. Угрюмов М.В. От генома до целостного организма. Научный мир. - 2014. - 520с.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. DSM-5. Washington DC: American Psychiatric Publishing. - 2013.
10. Ballmaier M., Narr K.L., Toga A.W. et al. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression // Am J Psychiatry. - 2008. -Vol.165. - P.229-237.
11. Belmaker, R.H., Agam, G. Major depressive disorder // N. Engl. J. Med. - 2008. - Vol.358. - P.55-68.
12. Biringer E, Arvid R, Anders L. A review of modern antidepressants’ effects on neurocognitive function // Curr Psychiatry Rev. - 2009. - Vol.5. - P.164-174.
13. Boldrini M., Underwood M.D., Hen R. et al. Antidepressants increase neural progenitor cells in the human hippocampus // Neuropsychopharmacology. - 2009. - Vol.34. - P. 2376-2389.
14. Bora E., Harrison B.J., Davey, C.G. et al. Meta-analysis of volum etricabnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder // Psychol. Med. - 2012. - Vol.42. - P. 671-681.
15. Bortolato B., Miskowiak K.W., Köhler C. A. et al. Cognitive remission: a novel objective for the treatment of major depression? // BMC Medicine. - 2016. - Vol. 14(9). - doi10.1186/s12916-016-0560-3
16. Bothwell M. NGF, BDNF, NT3 and NT4 // Handb Exp Pharmacol. - 2014. - Vol.220.-P. 3-15. doi: 10.1007/978-3-642-45106-5_1
17. Boulengera J-P., Loftb H., Olsen C. K. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder // International Clinical Psychopharmacology. - 2014. - Vol.29. - P. 138-149.
18. Burvill P.W., Johnson G.A., Jamrozik K.D. et al. Prevalence of depression after stroke: the Perth Community Stroke Study // Br J Psychiatry. -1995. - Vol.166. - P. 320-327.
19. Cai N., Bigdeli T., Kretzschmar W. et al. Sparse whole-genome sequencing identifies two loci for major depressive disorder // Nature. - 2015. - Vol.523. - P. 588-591.
20. Cattaneo A., Bocchio-Chivetto L., Zanardini R. et al. Reduced peripheral brain-derived neurotropgic factor mRNA levels are normalized by antidepressant treatment // Int. J. Neuropsychopharmacol. - 2010. - Vol. 13. - P. 103-108.
21. Conradi H.J., Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study //Psychol Med. - 2011. - Vol.41. - P. 1165-1174.
22. Chen L.S., Eaton W.W., Gallo J.J. et al. Empirical examination of current depression categories in a population-based study: Symptoms, course, and risk factors // Am J Psychiatry. - 2000. - Vol.157. - P. 573-580.
23. Demuro A., Min E., Kayed R. et alCalcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers // The Journal of biological chemistry. - 2005. - Vol.280. -№17. - P. 17294-17300.
24. Demuro A., Smith M., Parker I. Single-channel Ca2+ imaging implicates Aß1-42 amyloid pores in Alzheimer’s disease pathology // J. Cell Biol. - 2011. - Vol. 195. - №3. - P. 515-524
25. Eastwood M.R., Rifat S.L., Nobbs H., et al. Mood disorder following cerebrovascular accident // Br J Psychiatry. -1989. - Vol.154. - P. 195-200.
26. Fava M. Pharmacological approaches to the treatment of residual symptoms // J Clin Psychiatry. - 2006. - Vol.20. - P. 29-34.
27. Fedoroff J.P., Starkstein S.E., Parikh R.M. et al. Are depressive symptoms non-specific in patients with acute stroke? // Am J Psychiatry. -1991. - Vol.148(9). - P. 1172-1176.
28. Frodl, T., O’ Keane, V. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans // Neurobiol. Dis. - 2013. - Vol.52. - P. 24-37.
29. Gotlib I.H., Joormann J. Cognition and Depression: Current Status and Future Directions // Annu Rev Clin Psychol. - 2010. - Vol.6. - P. 285-312.
30. Gualteri C.T., Johnson L.G., Benedict K.B. Neurocognition in depression: patients on and off medication versus healthy comparison subjects. // J Neuropsychiatry Clin Neurosci. - 2006. - Vol.18. - P. 217-225.
31. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology // Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs. - P. 218-222.
32. Hall J.R., O’Bryant S.E., Johnson L. et al. Depression and Brain-Derived Neurotrophic Factor Levels in Alzheimer Disease // Neuroscience & Medicine. - 2011. - Vol.2. - P. 43-47.
33. Hammar A, Ardal G. Cognitive functioning in major depression - a summary // Front Hum Neurosci. - 2009. - Vol.3. - P. 26.
34. Heiden A., Kettenbach J., Fischer P. et al. White matter hyperintensities and chronicity of depression // J Psychiatr Res. - 2005. -Vol.39(3). - P. 285-293.
35. Hickie I., Naismith S., Ward P.B. et al. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression // Br J Psychiatry. - 2005. - Vol.186. - P. 197-202.
36. Jaeger J., Berns S., Uzelac S. et al. Neurocognitive deficits and disability in major depressive disorder // Psychiatry Res. - 2006. - Vol.145. - P. 39-48.
37. John E.H., Lophaven S., Olsen C.K. Which Cognitive Domains are Improved by Treatment with Vortioxetine? // International Journal of Neuropsychopharmacology. - 2016. - Vol.19(10). - P. 1-6.
38. Katona C., Hansen T., Olsen C.K. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder // Int. Clin. Psychopharmacol. - 2012. - Vol. 27. - №4. - P. 215-223.
39. Kempton M.J., Salvador Z., Munafà M.R.et al. Structural neuroimaging studies in major depressive disorder: meta-analysis and comparison with bipolar disorder // Arch Gen Psychiatry. - 2011. - Vol.68. - P. 675-690.
40. Kessing L.V. Course and cognitive outcome in major affective disorders // Danish Medical Journal. - 2015. - Vol.62(11). - P. 51-60.
41. Klomp A., Vaclavu L., Meerhoff G.F. et al. Effects of Chronic Fluoxetine Treatment on Neurogenesis and Tryptophan Hydroxylase Expression in Adolescent and Adult Rats // PLoS oNe. - 2014. - Vol.9(5). - e97603. doi:10.1371/journal.pone.0097603
42. Koolschijn P.C., van Haren N.E., Lensvelt-Mulders G.J. et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. // Hum Brain Mapp. - 2009. Vol. 30. - P. 3719-3735.
43. Kunugi H., Hori H., Adachi N. et al. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depressionpcn. // Psychiatry Clin Neurosci. - 2010. - Vol. б4(5). P. 447-459.
44. Li L., Ma N., Li Z. et al. Prefrontal white matter abnormalities in young adult with major depressive disorder: a diffusion tensor imaging study. // Brain Res. - 2007.- Vol.1168. - P. 124-128.
45. Lingjaerde O., Ahlfors U.G., Bech P. et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients // Acta Psychiatr Scand Suppl. - 1987. - Vol.334. - P. 1-100.
46. Lundbeck H. BrintellixTM (vortioxetine hydrobromide tablets): US prescribing information // 2013. http://www.accessdata.fda.gov/drugsatfda_docs/ label/2013/204447s000lbl.pdf. Accessed 20 June 2014.
47. Lundbeck H. Brintellix TM (vortioxetine tablets): EU summary of product characteristics. // 2014.http:// www.ema.europa.eu/docs/en_GB/document_library/ EPAR_- Product_Information/human/002717/ WC500159449.pdf. Accessed 20 June 2014.
48. Mahableshwarkar A., Zajecka J., Jacobson W. et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder // Neuropsychopharmacology. - 2015. - Vol.40(8). - P. 2025-2037.
49. Marazziti D., Consoli G., Picchetti M. et al. Cognitive impairment in major depression // Eur J Pharmacol. - 2010. - Vol.626. - P. 83-86.
50. McClintock S.M., Husain M.M., Wisniewski S.R. Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication // J Clin Psychopharmacol. - 2011. - Vol.31. - P. 180-186.
51. McIntyre R.S. Using measurement strategies to identify and monitor residual symptoms // J Clin Psychiatry. - 2013. - Vol.74(2). - P. 14-18.
52. McIntyre R.S., Xiao H.X., Syeda K. et al. The prevalence, measurement and treatment of the cognitive dimension/domain in major depressive disorder // CNS Drugs. - 2015. - Vol.29. - P. 577-589.
53. McIntyre R.S., Lophaven S., Olsen C.K. A randomized, doubleblind, placebo-controlled study of vortioxetine on cognitive function in depressed adults // Int. J. Neuropsychopharmacol. - 2014. - Vol.17(10). - P. 1557-1567. doi:10.1017/S1461145714000546.
54. McNair D., Khan R. J. Self-assessment of cognitive deficit in geriatric psychopharmacology / T. Crook, S. Ferris, R. Bartus R. - New Canaan, CT: Mark Powley Associaters Inc., 1983. - P. 137-143.
55. Mendez-Davida I., Henb R. , Gardier A.M. et al. Adult hippocampal neurogenesis: An actor in the antidepressant-like action // Annales Pharmaceutiques Françaises. - 2013. - Vol.71. - P. 143-149.
56. Miskowiakn K.W., Ott C.V., Petersen J.Z. et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field // European Neuropsychopharmacology. -2016. - Vol.26. - P. 1845-1867.
57. Montgomery S.A., Nielsen R.Z., Poulsen L.H. et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. // Hum Psychopharmac Clin Exp. - 2014. - Vol. 29. - P. 470-482.
58. Papakostas G.I. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice // J Clin Psychiatry. - 2014. - Vol.75. - P. 8-14.
59. Paykel E.S., Ramana R., Cooper Z. et al. Residual symptoms after partial remission - an important outcome in depression. // Psychological Medicine. -1995. - Vol.25. - P. 1171-1180.
60. Pettit J.W., Lewinsohn P.M., Joiner T.E. Propagation of major depressive disorder: relationship between first episode symptoms and recurrence //Psychiatry Res. - 2006. - Vol.141. - P. 271-278.
61. Pfeffer R.I., Kurosaki T.T., Harrah C.H. et al. Measurement of functional activities in older adults in the community // J Gerontol. - 1982. Vol.37. - P. 323-329.
62. Pittenger C. Disorders of memory and plasticity in psychiatric disease. // Dialogues Clin Neurosci. - 2013. -Vol. 15(4). - P.455-463.
63. Posner K., Brown G.K., Stanley B. et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. // The American Journal of Psychiatry. -2011. - Vol.168 (12). - P. 1266-1277.
64. Ries M.L., Wichmann A., Bendlin R.B. et al. Posterior cingulate and lateral parietal gray matter volume in older adults with depressive symptoms // Brain Imaging Behav. - 2009. Vol.3. - P. 233-239.
65. Schmaal L., Hibar D.P., Sämann P.G. et al. Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group // Mol. Psychiatry. - 2016. - Vol.21. - P. 806-812.
66. Sheline, Y.I. Depression and the hippocampus: cause or effect? // Biol. Psychiatry. - 2011. - Vol.70. - P. 308-309.
67. Sheline Y.I., Price J.L., Yan Z. et al. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus // Proc. Natl. Acad. Sci. U.S.A. - 2010.-Vol.107. - P. 11020-11025.
68. Shen Z., Cheng Y., Yang S. et al. Changes of grey matter volume in first-episode drug-naive adult major depressive disorder patients with different age onset // Neuroimage: Clinical - 2016. - №12. - P. 492-498.
69. Smith K. Mentalhealth: A world of depression. A global view of the burden caused by depression // Nature. - 2014. -Vol.515. - P. 180-181.
70. Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics // Expert Opin Drug Metab Toxicol. - 2014. - Vol.10(5). - P. 721-746.
71. Srinivasan S., Shariff M., Bartlett S.E. The role of the glucocorticoids in developing resilience to stress and addiction // Frontiers in Psychiatry. - 2013. - Vol. 4. - Article 68. - doi: 10.3389/ fpsyt.2013.00068
72. Theunissen E.L., Street D., Hojer A.M. et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition // Clin. Pharmacol. Ther. - 2013. - Vol.93. - №6. - P. 493-501.
73. Trivedi M.H., Greer T.L. Cognitive dysfunction in unipolar depression: Implications for treatment // J. of Affective disorders. - 2014. - Vol.152-154. - P. 19-27.
74. Videbech, P., Ravnkilde, B. Hippocampal volume and depression: a meta-analysis of MRI studies. // Am. J. Psychiatry. - 2004. - Vol.161. - P. 1957-1966.
75. Wang Y., Nomikos G.G., Karim A. et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTC study // Clin. Pharmacol. Drug Dev. - 2013. - Vol. 2. - №4. - P. 298-309.
76. WHO Report by Secretariat.-2011. Available at: http://apps.who. int/gb/ebwha/pdf_filrs/EB 13 0_9-en.pdf
77. Yoshii A., Paton C.M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity and disease//Dev. Neurobiol. - 2010. - Vol.70. - P. 304-322.
Review
For citations:
Zhitkova Yu.V., Hasanova D.R. Cognitive dysfunction in elderly patients with depression based on chronic brain ischemia: vortioxetine (Brintellix) experience. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2017;(4):81-88. (In Russ.)
Views:
2000
Email this article 